Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of BioCentury, Week in Review: Sales and Marketing

BioCentury, Week in Review Current Issue
  • Alimera Sciences, pSivida sales and marketing update

    Alimera Sciences Inc. (NASDAQ:ALIM), Alpharetta, Ga. pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Mass. Business: Ophthalmic Alimera launched Iluvien fluocinolone acetonide intravitreal implant in Germany to treat …

    Published on 5/13/2013
  • Biotie, Lundbeck sales and marketing update

    Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology H. Lundbeck launched Selincro nalmefene in the U.K. to reduce alcohol consumption in adults with …

    Published on 5/13/2013
  • Cancer Genetics sales and marketing update

    Cancer Genetics Inc. (OTCBB:CGIX), Rutherford, N.J. Business: Diagnostic Cancer Genetics launched its genomic microarray UroGenRA Kidney for kidney cancer diagnosis, subtyping and treatment selection. The assay is CLIA …

    Published on 5/13/2013
  • Concordia, Shionogi sales and marketing update

    Concordia Pharmaceuticals Inc., Fort Lauderdale, Fla. Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507), Osaka, Japan Business: Pharmaceuticals Concordia acquired from Shionogi rights to ADHD drug Kapvay clonidine and oral …

    Published on 5/13/2013
  • Cornerstone Therapeutics, Digestive Care sales and marketing update

    Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C. Digestive Care Inc., Bethlehem, Pa. Business: Gastrointestinal Digestive Care granted Cornerstone exclusive, U.S. rights to market Pertzye pancrelipase for 10 …

    Published on 5/13/2013
  • Dainippon Sumitomo, Ono Pharmaceutical sales and marketing update

    Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506), Osaka, Japan Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528), Osaka, Japan Business: Neurology The pharmas expanded a 2011 deal to co-develop and co-…

    Published on 5/13/2013
  • Genomic Health sales and marketing update

    Genomic Health Inc. (NASDAQ:GHDX), Redwood City, Calif. Business: Diagnostic Genomic Health launched its Oncotype DX prostate cancer assay worldwide to predict adverse pathology in patients with early stage, low-risk …

    Published on 5/13/2013
  • Intas Pharmaceuticals sales and marketing update

    Intas Pharmaceuticals Ltd., Ahmedabad, India Business: Biosimilars, Cancer Intas launched Mabtas rituximab in India to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) alone or in combination …

    Published on 5/13/2013
  • Martindale Pharma sales and marketing update

    Martindale Pharma, Brentwood, U.K. Business: Neurology, Drug delivery Martindale launched Prenoxad Injection naloxone hydrochloride in the U.K. to treat acute opioid-related overdose. The product, which costs 18 ($28.05…

    Published on 5/13/2013
  • Paladin, Pernix Therapeutics sales and marketing update

    Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Pernix Therapeutics Holdings Inc. (NASDAQ:PTX), the Woodlands, Texas Business: Neurology Paladin launched Silenor doxepin in Canada for the treatment and symptomatic relief …

    Published on 5/13/2013
  • Shionogi sales and marketing update

    Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507), Osaka, Japan Business: Endocrine/Metabolic Shionogi launched Osphena ospemifene in the U.S. to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal …

    Published on 5/13/2013
  • Galderma sales and marketing update

    Galderma S.A., Lausanne, Switzerland Business: Dermatology Galderma launched Tri-Luma cream in the U.S. to treat moderate to severe melisma of the face for up to eight weeks. Tri-Luma is a topical combination of …

    Published on 2/18/2013
  • Hisamitsu sales and marketing update

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530; Osaka:4530), Tosu, Japan Business: Endocrine/Metabolic Hisamitsu's Noven Pharmaceuticals Inc. subsidiary launched Minivelle estradiol transdermal system in the U.S. to …

    Published on 2/18/2013
  • Hyperion sales and marketing update

    Hyperion Therapeutics Inc. (NASDAQ:HPTX), South San Francisco, Calif. Business: Endocrine/Metabolic On a Feb. 4 conference call regarding FDA's approval of Ravicti glycerol phenylbutyrate, Hyperion said it estimated a …

    Published on 2/18/2013
  • Innovus, Prospector Capital Partners II LLC sales and marketing update

    Innovus Pharmaceuticals Inc. (OTCBB:INNV), San Diego, Calif. Prospector Capital Partners II LLC, San Diego, Calif. Business: Gastrointestinal, Dermatology Innovus signed a binding term sheet to acquire nine prescription…

    Published on 2/18/2013
  • Myriad Genetics, Saladax sales and marketing update

    Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Saladax Biomedical Inc., Bethlehem, Pa. Business: Diagnostic Saladax said Myriad will return North American rights to its My5-FU diagnostic test following a …

    Published on 2/18/2013
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo Nordisk said it will launch diabetes drug Tresiba insulin degludec in Japan "shortly after" the drug is listed on Japan's …

    Published on 2/18/2013
  • Reckitt Benckiser, Bristol-Myers sales and marketing update

    Reckitt Benckiser Group plc (LSE:RB), Slough, U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Pharmaceuticals Reckitt Benckiser will acquire exclusive commercialization and distribution rights to OTC …

    Published on 2/18/2013
  • AIBioTech sales and marketing update

    American International Biotechnology LLC, Richmond, Va. Business: Diagnostic The company launched its LDT asparaginase assay in the U.S. and Canada. The assay measures L-asparaginase levels in patients receiving …

    Published on 2/11/2013
  • Astellas sales and marketing update

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Endocrine/Metabolic, Infectious Astellas said in its fiscal 3Q earnings for the period ending Dec. 31, 2012 that it launched three products. Astellas said that …

    Published on 2/11/2013
  • Biotest sales and marketing update

    Biotest AG (Xetra:BIO), Dreieich, Germany Business: Autoimmune, Diagnostic Biotest's Biotest Pharmaceuticals Corp. subsidiary launched IV Bivigam 10% human immune globulin in U.S. to treat primary immune deficiency …

    Published on 2/11/2013
  • Dyax, Novellus Biopharma AG sales and marketing update

    Dyax Corp. (NASDAQ:DYAX), Burlington, Mass. Novellus Biopharma AG, Switzerland Business: Inflammation Dyax and Novellus partnered to develop and commercialize Kalbitor ecallantide in select regions in Latin America to …

    Published on 2/11/2013
  • Oasmia, Pharmasyntez sales and marketing update

    Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Pharmasyntez, Irkutsk, Russia Business: Cancer Oasmia granted Pharmasyntez exclusive commercialization and distribution rights to Paclical micellular paclitaxel in …

    Published on 2/11/2013
  • Sequenom sales and marketing update

    Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Business: Diagnostic Sequenom said it expanded the range of chromosomal abnormalities reported by the MaterniT21 Plus laboratory-developed test (LDT) to include fetal sex …

    Published on 2/11/2013
  • Supernus sales and marketing update

    Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Business: Neurology Supernus launched Oxtellar XR oxcarbazepine in the U.S. as an adjunctive therapy in the treatment of partial seizures in adults and …

    Published on 2/11/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?